The 'Week in Review' - 16 February
It was not an easy or enjoyable decision, but the stakes are very high for Australian patients, given the apparent risks to the future of funded access to health technologies. We also discuss Senate E...
16 Helmi 202429min
HTA Review options paper interview - 31 January
With just nine days remaining for stakeholders to submit their feedback on the Health Technology Assessment Review options paper, patients must have access to all pertinent information. BioPharmaDispa...
13 Helmi 202431min
The 'Week in Review' - 9 February
The 'Swiss cheese' theory might explain why history is constantly repeating itself and why action is required to avoid the worst aspects of the proposals in the HTA Review options paper.
9 Helmi 202427min
The 'Week in Review' - 2 February
We are back for 2024 with no end of issues to discuss, starting with the HTA review options paper and the coincidence of many reviews and processes delivering outcomes just ahead of the May Budget.
2 Helmi 202441min
The 'End of Year Review' - 19 December
Looking ahead, the industry needs to find a framework for challenging the government on its decision-making, and awards that recognise the bad, the ugly and the good in 2023. Timeline 0:00 - 12:00 -...
18 Joulu 202356min
The 'Week in Review' - 8 December
More silence on a critical social issue. The report of the NDIS review delivers a range of recommendations, including the adoption of an evidence-based funding framework, but is it practical or even p...
8 Joulu 202330min
The 'Week in Review' - 1 December
We discuss the apparent reluctance to speak out on one important issue. The Government's entirely predictable response to the inquiry on access to new medicines and novel medical technologies, why dis...
1 Joulu 202337min
The 'Week in Review' - 24 November
The power of language and the habit governments have of weaponising the word 'sustainable'. How the term has been used to 'gently' justify breaking election commitments and its wider impact on policy ...
23 Marras 202335min
